Discover the latest on Rhythm Pharmaceuticals, Inc. and its asset, imcivree, targeting rare obesity disorders and potential ...

SOUTH SAN FRANCISCO, CA, USA I 05, 2024 I Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical ...

Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

The therapy failed to slow disease progression in patients with early Alzheimer’s in the INVOKE-2 trial (NCT04592874).

Zinc supplementation was started. Genetic testing done simultaneously showed compound heterozygous mutations in SLC39A4 in ...